Abiosciences
Private Company
Funding information not available
Overview
Abiosciences is a private, pre-clinical stage biotechnology company founded in 2005 that integrates single-cell and spatial omics with AI/ML-driven bioinformatics for drug discovery. Its business model is dual-faceted, involving collaborative research partnerships with biopharma companies and the out-licensing of validated targets and therapeutic antibodies. While the company appears to be pre-revenue, it positions itself as a one-stop solution from data generation to insight, aiming to accelerate the development of first-in-class therapeutics.
Technology Platform
Integrated platform combining single-cell genomics, spatial omics, and proprietary AI/ML-driven bioinformatics for target and biomarker discovery.
Opportunities
Risk Factors
Competitive Landscape
Abiosciences competes in the crowded field of AI/ML-driven drug discovery and single-cell analytics. Competitors range from large tools companies (e.g., 10x Genomics) to pure-play bioinformatics and discovery platforms (e.g., Recursion, Insitro). Its differentiation lies in its vertical integration of wet-lab omics generation with proprietary computational analysis.